Last reviewed · How we verify
Clobetasol Propionate, 0.05%
Clobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Clobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema), Alopecia areata, Lichen sclerosus.
At a glance
| Generic name | Clobetasol Propionate, 0.05% |
|---|---|
| Also known as | Clobex® Spray, Clobex® Spray, 0.05% |
| Sponsor | Galderma R&D |
| Drug class | Topical corticosteroid (Class I, super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
As a Class I (super-potent) topical corticosteroid, clobetasol propionate activates intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. This results in rapid anti-inflammatory, antipruritic, and vasoconstrictive effects on affected skin. The 0.05% formulation is among the highest-strength topical corticosteroids available.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema)
- Alopecia areata
- Lichen sclerosus
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Systemic corticosteroid absorption (with prolonged use or occlusion)
- Contact dermatitis
Key clinical trials
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo (EARLY_PHASE1)
- Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus. (NA)
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- Laser vs Clobetasol for Lichen Sclerosus (PHASE3)
- To Compare Inflammatory Biomarkers Before and After Treatment With Clobetasol or Fractional CO2 Laser, in Women With Histologically Confirmed Vulvar Lichen Sclerosus, Without Prior Corticosteroid Treatment. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobetasol Propionate, 0.05% CI brief — competitive landscape report
- Clobetasol Propionate, 0.05% updates RSS · CI watch RSS
- Galderma R&D portfolio CI